ArticleCirculation2014
CD82 restrains pathological angiogenesis by altering lipid raft clustering and CD44 trafficking in endothelial cells.
Abstract read
In one paragraph
Article in Circulation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- Interaction between CD82 and integrin αVβ3 selectively regulates collective movement of tumor cells via endolysosomal trafficking.Cellular and molecular life sciences : CMLS · 2026Article
- Cut the fat: targeting cholesterol and lipid metabolism in glioblastoma.Cell death & disease · 2025Review
- Tetraspanin-enriched membrane domains regulate vascular leakage by altering membrane cholesterol accessibility to balance antagonistic GTPases.Nature cardiovascular research · 2025Article
- Tetraspanin CD82 regulates transforming growth factor-β signaling in hematopoietic stem and progenitor cells.Molecular biology of the cell · 2025Article
- Unveiling the Potential of Migrasomes: A Machine-Learning-Driven Signature for Diagnosing Acute Myocardial Infarction.Biomedicines · 2024Article
- Evaluating the effects of various ethanolic medicinal plant extracts on metastatic breast cancer proliferation, invasion, and expression of a novel potential drug target; CD82 metastatic suppressor protein, and on in vivo angiogenesis using the ex ovo yolk sac membrane (YSM) assay.Journal of cancer research and clinical oncology · 2024Article
- Tetraspanin Tspan8 restrains interferon signaling to stabilize intestinal epithelium by directing endocytosis of interferon receptor.Cellular and molecular life sciences : CMLS · 2023Article
- Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations.Blood advances · 2023Article
- CD44 promotes angiogenesis in myocardial infarction through regulating plasma exosome uptake and further enhancing FGFR2 signaling transduction.Molecular medicine (Cambridge, Mass.) · 2022Article
- The lipid rafts in cancer stem cell: a target to eradicate cancer.Stem cell research & therapy · 2022Review
- Article
- A Functional Network Model of the Metastasis Suppressor PEBP1/RKIP and Its Regulators in Breast Cancer Cells.Cancers · 2021Article
- Tetraspanin CD82 regulates S1PRStem cell reports · 2021Article
- KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state.Journal of hematology & oncology · 2021Article
- A Bioinformatics Perspective on the Links Between Tetraspanin-Enriched Microdomains and Cardiovascular Pathophysiology.Frontiers in cardiovascular medicine · 2021Article
- CD82-TRPM7-Numb signaling mediates age-related cognitive impairment.GeroScience · 2020Article
- Tetraspanin CD82 interaction with cholesterol promotes extracellular vesicle-mediated release of ezrin to inhibit tumour cell movement.Journal of extracellular vesicles · 2020Article
- Migrasome and Tetraspanins in Vascular Homeostasis: Concept, Present, and Future.Frontiers in cell and developmental biology · 2020Review
- Tetraspanin CD82 Organizes Dectin-1 into Signaling Domains to Mediate Cellular Responses toJournal of immunology (Baltimore, Md. : 1950) · 2019Article
- The tetraspanin CD82 regulates bone marrow homing and engraftment of hematopoietic stem and progenitor cells.Molecular biology of the cell · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 2 countries.
Quan WeiFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Feng ZhangFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Mekel M RichardsonFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Nathan H RoyFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
William RodgersFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Yuechueng LiuFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Wenyuan ZhaoFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Chenying FuFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Yingjun DingFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Chao HuangFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Yuanjian ChenFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Yao SunFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Lexi DingFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Yang HuFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Jian-Xing MaFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Michael E BoultonFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Satish PasulaFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Jonathan D WrenFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Satoshi TanakaFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Xiaolin HuangFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Markus ThaliFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Günter J HämmerlingFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.).
Xin A ZhangFrom the West China Hospital, Sichuan University, Chengdu, China (Q.W.); University of Oklahoma Health Science Center, Oklahoma City (Q.W., F.Z., M.M.R., W.R., Y.L., C.F., Y.D., C.H., L.D., Y.H., J.M., X.A.Z.); University of Vermont, Burlington (N.H.R., M.T.); University of Tennessee, Memphis (W.Z., Y.C., Y.S.); Tongji Hospital, Wuhan, China (Y.D., X.H.); Indiana University, Indianapolis (M.E.B.); Oklahoma Medical Research Foundation, Oklahoma City (S.P., J.D.W.); and German Cancer Research Center, Heidelberg, Germany (S.T., G.J.H.). xin-zhang-1@ouhsc.edu.
Indiana University – Purdue University Indianapolis · USSichuan University · CNUniversity of Tennessee Health Science Center · USOklahoma Medical Research Foundation · USUniversity of Vermont · USTongji Hospital · CNWest China Hospital of Sichuan University · CN
Funding
Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2MVermont Immunobioloigy/ Infectious Diseases CenterP20GM103496 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BUDD, RALPH C · 2012 to 2015
$8.7MMolecular Mmechanism of KAI1/CD82-mediated SuppressionR01CA096991 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ZHANG, XIN A · 2004 to 2014
$2.8MVermont Immunology/Infectious Diseases Training GrantT32AI055402 · NIAID · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI GARY E WARD · 2005 to 2026
$2.7MMolecular regulation of HIV-1 assembly, release and cell-to-cell transmissionR01AI080302 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI THALI, MARKUS · 2009 to 2013
$1.9MNCI NIH HHS CA096991NCI NIH HHS R01 CA096991NIAID NIH HHS R01 AI080302NIAID NIH HHS T32 AI055402NIGMS NIH HHS P20 GM103496NIGMS NIH HHS U54 GM104938
Abstract
backgroundAngiogenesis is crucial for many pathological processes and becomes a therapeutic strategy against diseases ranging from inflammation to cancer. The regulatory mechanism of angiogenesis remains unclear. Although tetraspanin CD82 is widely expressed in various endothelial cells (ECs), its vascular function is unknown. METHODS AND
resultsAngiogenesis was examined in Cd82-null mice with in vivo and ex vivo morphogenesis assays. Cellular functions, molecular interactions, and signaling were analyzed in Cd82-null ECs. Angiogenic responses to various stimuli became markedly increased upon Cd82 ablation. Major changes in Cd82-null ECs were enhanced migration and invasion, likely resulting from the upregulated expression of cell adhesion molecules such as CD44 and integrins at the cell surface and subsequently elevated outside-in signaling. Gangliosides, lipid raft clustering, and CD44-membrane microdomain interactions were increased in the plasma membrane of Cd82-null ECs, leading to less clathrin-independent endocytosis and then more surface presence of CD44.
conclusionsOur study reveals that CD82 restrains pathological angiogenesis by inhibiting EC movement, that lipid raft clustering and cell adhesion molecule trafficking modulate angiogenic potential, that transmembrane protein modulates lipid rafts, and that the perturbation of CD82-ganglioside-CD44 signaling attenuates pathological angiogenesis.
Indexed as
AnimalsCell Adhesion MoleculesCell LineCell MovementCytoskeletonEndocytosisEndothelial CellsGangliosidesHyaluronan ReceptorsKangai-1 ProteinMembrane MicrodomainsMice, KnockoutNeovascularization, PathologicProtein TransportSignal TransductionCd44 protein, mouseCd82 antigen, mouseCell Adhesion MoleculesGangliosidesHyaluronan ReceptorsKangai-1 Proteincell movementendocytosismembrane microdomainsneovascularization, pathological
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.